Rodriguez Raul R's Form 4 filing
Rigel Pharmaceuticals Inc (RIGL) · filed Feb 7, 2023
- Accession no.
- 0001140361-23-005036
- Filed
- Feb 7, 2023
- Trade date
- Jan 26-Feb 6, 2023
- Filing delay
- 12 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $35.6K. It was filed 12 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rodriguez Raul RCIK 0001190279 | Director, Officer (CEO, President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 26, 2023 | Common Stock | AGrant or awardAcquired | +300,000 | $0.00 | $0 | 1,701,053 | Direct | |
| Feb 6, 2023 | Common Stock | SSaleDisposed | −20,340 | $1.75 | −$35,595 | 1,680,713 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 26, 2023 | Common Stock | AGrant or awardAcquired | +600,000 | $0.00 | $0 | 600,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.